| __timestamp | CymaBay Therapeutics, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 15823000 | 84580000 |
| Thursday, January 1, 2015 | 17026000 | 86943000 |
| Friday, January 1, 2016 | 15941000 | 84493000 |
| Sunday, January 1, 2017 | 18938000 | 64988000 |
| Monday, January 1, 2018 | 58124000 | 74951000 |
| Tuesday, January 1, 2019 | 83837000 | 62331000 |
| Wednesday, January 1, 2020 | 35882000 | 28607000 |
| Friday, January 1, 2021 | 64542000 | 32228000 |
| Saturday, January 1, 2022 | 67995000 | 46600000 |
| Sunday, January 1, 2023 | 80118000 | 54886000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, CymaBay Therapeutics, Inc. and Dynavax Technologies Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, CymaBay's R&D expenses surged by over 400%, peaking in 2023, while Dynavax's spending showed a more volatile pattern, with a notable decline of about 35% from its 2015 peak.
This divergence highlights CymaBay's consistent focus on innovation, particularly in recent years, as it increased its R&D budget by 22% from 2022 to 2023. In contrast, Dynavax's fluctuating investment may reflect strategic shifts or external challenges. As the biotech landscape evolves, these spending patterns could significantly impact each company's future breakthroughs and market positioning.
Comparing Innovation Spending: Novo Nordisk A/S and Dynavax Technologies Corporation
Analyzing R&D Budgets: Novartis AG vs Dynavax Technologies Corporation
Comparing Innovation Spending: Sanofi and CymaBay Therapeutics, Inc.
Analyzing R&D Budgets: Zoetis Inc. vs Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
R&D Insights: How Exelixis, Inc. and CymaBay Therapeutics, Inc. Allocate Funds
Comparing Innovation Spending: Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
R&D Spending Showdown: Alpine Immune Sciences, Inc. vs CymaBay Therapeutics, Inc.
Comparing Innovation Spending: CymaBay Therapeutics, Inc. and Amicus Therapeutics, Inc.
Analyzing R&D Budgets: CymaBay Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing Innovation Spending: Vericel Corporation and Dynavax Technologies Corporation
Catalyst Pharmaceuticals, Inc. or Dynavax Technologies Corporation: Who Invests More in Innovation?